The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment of poor-risk non seminomatous germ-cell tumors (NSGCT) adapted by tumor marker decline: A 7-year multicenter real-world experience.
 
Sara Faouzi
No Relationships to Disclose
 
Leonor Chaltiel
No Relationships to Disclose
 
Natacha Naoun
No Relationships to Disclose
 
Marion Rolland
No Relationships to Disclose
 
Clement Dumont
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Merck Serono; MSD; Pfizer
Travel, Accommodations, Expenses - Ipsen; Janssen; Janssen; MSD; Pfizer
 
Marine Gross-Goupil
No Relationships to Disclose
 
Lionnel Geoffrois
Honoraria - BMS; Eisai Europe; Ipsen; Merck serono; MSD; Pfizer
Consulting or Advisory Role - Ipsen; Merck Serono
Travel, Accommodations, Expenses - Ipsen; Merck Serono; MSD Oncology
 
Emmanuelle Bompas
No Relationships to Disclose
 
Brigitte Laguerre
Honoraria - Astellas Pharma; Astellas Pharma; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; ipsen; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; BMS; IPSEN; Ipsen; Janssen Oncology; MSD Oncology; Novartis AAA; Pfizer; Pfizer; Pfizer
 
Guilhem Roubaud
Honoraria - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen-Cilag (Inst)
Consulting or Advisory Role - AAA/Endocyte/Novartis (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Ipsen (Inst); Janssen-Cilag; Merck/Pfizer (Inst); Pfizer (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen-Cilag
 
Magalie Tardy
No Relationships to Disclose
 
Aude Flechon
Honoraria - AAA HealthCare; Astellas Pharma; AstraZeneca; Bayer; BMS; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; NOVARTIS; PFIZER; Roche/Genentech; Sanofi/Aventis
Travel, Accommodations, Expenses - AAA HealthCare; Astellas Pharma; AstraZeneca; Bayer; BMS; IPSEN; Janssen-Cilag; MSD Oncology; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Constance Thibault
No Relationships to Disclose
 
Diego Tosi
Consulting or Advisory Role - Brenus Pharma; Mabqi; Tes Pharma
Research Funding - Bayer; Ipsen
Patents, Royalties, Other Intellectual Property - I have a pending patent on a new drug combination for prostate cancer treatment
Travel, Accommodations, Expenses - Advanced Accelerator Applications; AstraZeneca; Biogen (I); BMS; Ipsen; Medusas (I); Novartis; Pfizer
(OPTIONAL) Uncompensated Relationships - Brenus Pharma; Phost'in
 
Hakim Mahammedi
No Relationships to Disclose
 
Christine Chevreau
No Relationships to Disclose
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Novartis; Pfizer
 
Damien Pouessel
Honoraria - AAA/Endocyte/Novartis; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer/Astellas
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Eisai; Merck; MSD Oncology; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer